Nanobiotix S.A. (NANO.PA)
EUR 3.48
(1.93%)
EUR 3.48
(1.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -39.7 Million EUR | 30.4% |
| 2022 | -57.04 Million EUR | -21.36% |
| 2021 | -47 Million EUR | -39.93% |
| 2020 | -33.59 Million EUR | 34.03% |
| 2019 | -50.91 Million EUR | -67.79% |
| 2018 | -30.34 Million EUR | -16.07% |
| 2017 | -26.14 Million EUR | -19.48% |
| 2016 | -21.88 Million EUR | -28.69% |
| 2015 | -17 Million EUR | -77.92% |
| 2014 | -9.55 Million EUR | -17.33% |
| 2013 | -8.14 Million EUR | -52.79% |
| 2012 | -5.33 Million EUR | -1.61% |
| 2011 | -5.24 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -21.87 Million EUR | 0.0% |
| 2023 FY | -39.7 Million EUR | 30.4% |
| 2023 Q4 | -11.6 Million EUR | 0.0% |
| 2023 Q2 | -28.09 Million EUR | 0.0% |
| 2022 Q4 | -30.68 Million EUR | 0.0% |
| 2022 FY | -57.04 Million EUR | -21.36% |
| 2022 Q2 | -26.35 Million EUR | 0.0% |
| 2021 Q4 | -16.58 Million EUR | 0.0% |
| 2021 FY | -47 Million EUR | -39.93% |
| 2021 Q2 | -30.42 Million EUR | 0.0% |
| 2020 Q4 | -13.01 Million EUR | 0.0% |
| 2020 Q2 | -20.57 Million EUR | 0.0% |
| 2020 FY | -33.59 Million EUR | 34.03% |
| 2019 Q2 | -23.92 Million EUR | 0.0% |
| 2019 Q4 | -26.99 Million EUR | 0.0% |
| 2019 FY | -50.91 Million EUR | -67.79% |
| 2018 Q4 | -17.73 Million EUR | 0.0% |
| 2018 FY | -30.34 Million EUR | -16.07% |
| 2018 Q2 | -12.61 Million EUR | 0.0% |
| 2017 Q2 | -12.18 Million EUR | 0.0% |
| 2017 FY | -26.14 Million EUR | -19.48% |
| 2017 Q4 | -13.95 Million EUR | 0.0% |
| 2016 FY | -21.88 Million EUR | -28.69% |
| 2016 Q2 | -10.16 Million EUR | 0.0% |
| 2016 Q4 | -11.71 Million EUR | 0.0% |
| 2015 Q4 | -9.22 Million EUR | 0.0% |
| 2015 Q2 | -7.77 Million EUR | 0.0% |
| 2015 FY | -17 Million EUR | -77.92% |
| 2014 Q4 | -5.39 Million EUR | 0.0% |
| 2014 FY | -9.55 Million EUR | -17.33% |
| 2014 Q2 | -4.16 Million EUR | 0.0% |
| 2013 Q3 | -2.04 Million EUR | 52.27% |
| 2013 Q2 | -4.27 Million EUR | -109.52% |
| 2013 Q1 | -2.04 Million EUR | 0.0% |
| 2013 FY | -8.14 Million EUR | -52.79% |
| 2013 Q4 | -3.86 Million EUR | -89.27% |
| 2012 Q3 | -1.33 Million EUR | 0.0% |
| 2012 Q1 | -1.33 Million EUR | 0.0% |
| 2012 Q4 | -2.04 Million EUR | -53.25% |
| 2012 FY | -5.33 Million EUR | -1.61% |
| 2012 Q2 | -1.33 Million EUR | 0.0% |
| 2011 Q3 | -1.31 Million EUR | 0.0% |
| 2011 Q2 | -1.31 Million EUR | 0.0% |
| 2011 Q1 | -1.31 Million EUR | 0.0% |
| 2011 FY | -5.24 Million EUR | 0.0% |
| 2011 Q4 | -1.33 Million EUR | -1.01% |
| 2010 Q4 | -1.31 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -1028.482% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 73.128% |
| Adocia SA | -21.16 Million EUR | -87.6% |
| Aelis Farma SA | -5.07 Million EUR | -681.804% |
| Biophytis S.A. | -17.02 Million EUR | -133.173% |
| Advicenne S.A. | -7.03 Million EUR | -464.642% |
| genOway Société anonyme | 1.56 Million EUR | 2632.574% |
| IntegraGen SA | -171.39 Thousand EUR | -23062.329% |
| Medesis Pharma S.A. | -3.95 Million EUR | -902.654% |
| Neovacs S.A. | -8.74 Million EUR | -354.054% |
| NFL Biosciences SA | -3.74 Million EUR | -959.945% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 50245.89% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -1151.992% |
| Sensorion SA | -22.06 Million EUR | -79.936% |
| Theranexus Société Anonyme | -6.82 Million EUR | -481.433% |
| TME Pharma N.V. | -6.73 Million EUR | -489.371% |
| Valbiotis SA | -7.36 Million EUR | -438.817% |
| TheraVet SA | -1.57 Million EUR | -2427.524% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -95.144% |
| argenx SE | -272.91 Million EUR | 85.453% |
| BioSenic S.A. | -28.77 Million EUR | -37.953% |
| Celyad Oncology SA | -8.44 Million EUR | -369.934% |
| DBV Technologies S.A. | -67.26 Million EUR | 40.984% |
| Galapagos NV | 211.69 Million EUR | 118.753% |
| Genfit S.A. | -28.89 Million EUR | -37.399% |
| GeNeuro SA | -14.75 Million EUR | -169.025% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -158.127% |
| Innate Pharma S.A. | -7.57 Million EUR | -424.439% |
| Inventiva S.A. | -110.42 Million EUR | 64.048% |
| MaaT Pharma SA | -19.71 Million EUR | -101.349% |
| MedinCell S.A. | -25.03 Million EUR | -58.559% |
| Onward Medical N.V. | -36.18 Million EUR | -9.726% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -1084.034% |
| OSE Immunotherapeutics SA | -23 Million EUR | -72.586% |
| Oxurion NV | -18.96 Million EUR | -109.289% |
| Pharming Group N.V. | -9.75 Million EUR | -306.905% |
| Poxel S.A. | -35.09 Million EUR | -13.138% |
| GenSight Biologics S.A. | -26.22 Million EUR | -51.411% |
| Transgene SA | -22.32 Million EUR | -77.804% |
| Financière de Tubize SA | 88.15 Million EUR | 145.036% |
| UCB SA | 343 Million EUR | 111.574% |
| Valneva SE | -101.42 Million EUR | 60.859% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -40.075% |